Premier Research adds Patient Recruitment Expert to Team
News Feb 10, 2011
Mrs Robinson is a highly experienced patient recruitment specialist with considerable global CRO experience. In her previous roles, Mrs. Robinson developed and led a global team in the execution of patient feasibility, recruitment and retention planning which drew on the expertise of medical, regulatory and clinical operations colleagues and formed a close collaborative approach to protocol evaluation and data collection.
Her experience includes in-depth global feasibility and strategic patient recruitment and retention planning for clinical studies in all phases and across a broad range of therapeutic areas. She has worked in all geographies focusing in recent years on expanding markets in Central and Eastern Europe, Asia Pacific and South America.
Sue will provide operational oversight of Premier Research’s feasibility team and partner with the project teams to build patient recruitment and retention plans from initial feasibility assessment through to clinical phase completion.
"We are pleased to have Sue join our clinical team. As an organization, we have grown significantly and have established a need for someone of Sue’s caliber to lead our patient recruitment efforts,” said Chris Nowell, Vice President Europe. “Her global perspective and diverse expertise will strengthen our project teams and provide our sponsors with the confidence their project timelines will be achieved.”
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE